Search Results for theranos

Rounding up the funding rounds of 2015–and the deals some would like to see (?)

...lighter-hearted (I think) look at 2016 deals. IBM would buy athenahealth mainly for its EHR and practice management data, plus data aggregator Validic, to beef up Watson; 23andMe, past its two years of troubles after stepping on FDA Superman’s cape, would buy PatientsLikeMe (endangering its community shaped credibility? 23PatientsLikeMe?) and the best–Theranos bought by Boston Heart Diagnostics/Eurofin (EU lab testing giant), which would reduce this unicorn to a pony…but one that might make it. Theranos also made VentureBeat’s list of Likely Carcasses in the Valley of Unicorn Death (to quote the article’s author). Chris Seper’s Deals He’d Like To See.... Continue Reading

Silicon Valley’s betting on ‘citizen doctors’, ‘citizen science’ and useful data

...23andme is back in the good graces of the FDA after a two-year scuffle and back doing direct response TV here in the US. Scanadu’s two products, Vitals (formerly Scout) and Urine are still not through the long slog of FDA clearance. The jury’s out on Theranos. And all these companies, including ‘unicorn’ Theranos, are bleeding cash and nowhere near turning a profit. ModernLuxury. Hat tip to Dr Topol via Twitter, who had a patient-centered conversation with Dr Wachter that we covered back in September. Another recent podcast with Dr Wachter is here (Community Health Center radio). Update: ‘Citizen science’... Continue Reading

Is Theranos’ ‘blood testing for all’ a responsible selling proposition?

Theranos’ recent troubles on their blood testing (Walgreens halting expansion, FDA halting nanotainers as ‘uncleared medical devices’ and last week chain grocery/drugstore Safeway dropping their $350 million deal for 800 locations) have been well covered in media both here and elsewhere. But what if their Unique Selling Proposition–that people should have the ‘basic human right’ to order up their own inexpensive blood tests and then be responsible for their own interpretation–is counter-productive for many patients? After all, it’s what Theranos has been organized and raised $400 million+ on. Dr Robert Wachter of UCSF, who is no top-down Ezekiel-esque ‘nanny stater’,... Continue Reading

Theranos/FDA update: nanotainers are ‘uncleared medical devices’ investigator says of the validation phase of an unspecified Theranos device. Neither did it “ensure the device conforms to defined user needs and intended uses.” Theranos claims that the company addressed and corrected all the complaints within a week or less, and have documented same. The controversy over the nanotainers strike at the heart of Theranos’ Unique Selling Proposition (all the posed photos with CEO Elizabeth Holmes striking a Steve Jobs-like pose in the ash can?). Without it, they are just another lab testing company that is perhaps cheaper. Also FierceHealthIT and The Wall Street Journal (may be paywalled).... Continue Reading

Blood is drawn: Theranos responds vigorously to TTA re WSJ

From his very first interactions with Theranos, the reporter made abundantly clear that he considered Theranos to be a target to be taken down, and not simply the subject of an objective news story. The articles that appeared last week are the inevitable product of that approach.–Theranos Facts, 22 Oct Breaking news. Blood is drawn. A spokesperson for Theranos (from FTI Consulting), Ms Shea Maney, has responded directly to this Editor regarding the content of the Wall Street Journal article, previously covered here (The $9 billion question mark) along with followup in primarily Fortune but also commentary in the Health... Continue Reading

The Theranos Kerfuffle: a setback, but is it for the best? (updated)

...and press hype are bonkers and Stark Raving Mad, mit out a relationship to reality. There’s a buried but tasty piece of speculation on Theranos’ real market. Because of the makeup of the corporate board, heavy on government, retired military and defense types, Theranos’ real market may not be retail and consumer-driven, but governmental entities such as the Department of Defense. You do have to slog through the usual extraneous cracks about old, white male Republicans and Rupert Murdoch to get to it, though. Not that Theranos is the first company that’s ever played this game. Your Editor will go... Continue Reading

Is Theranos a $9 billion question mark?

Breaking News. According to an exposé published yesterday in The Wall Street Journal*, low-cost and fast growing small sample blood testing company Theranos [TTA 28 Aug] is not ‘doing what it says it does’. Four former employees allege that Theranos’ testing system, dubbed the Edison, which processes small finger-pricked blood samples collected in ‘nanotainers’, only handles a fraction of the tests claimed–19 out of 205. In a complaint to regulators, one Theranos employee accused the company of failing to report test results that raised questions about the precision of their proprietary Edison system–and that most of the tests were being... Continue Reading

Integrating inexpensive lab testing, imaging to EHR–and vice versa

In the Dr Eric Topol patient-driven world, personal lab testing would be walk in, keep retail hours and not even need a doctor’s order. That is the model for Theranos, a well-funded low cost blood testing company operating 43 centers in California, Arizona (no doctor order needed) and one Pennsylvania Walgreens. Their latest alliance is with EHR physician practice giant Practice Fusion, which claims about 112,000 doctors actively using its cloud-based, ad supported platform, claims to be the fastest growing US EHR with at present 100 million patient records. The Theranos reporting app, which also connects patients with doctors who... Continue Reading

Apps and wearables – developments over the summer

...wearables definition past breaking point, it would seem churlish not just to pop in the video of the first ever FAA-approved medicine delivery by a Flirtey drone. About as tenuous as the last link comes news too of the hugely impressive Theranos securing FDA waiver to take its blood tests out of the lab, so promoting point-of-care-testing (POCT) further. And finally, this mobihealthnews item entitled Class action lawsuit alleges Fitbit misled buyers with inaccurate sleep tracking, and this Iowa State university study on activity tracker accuracy reminds me that my Jawbone UP3 stopped tracking my sleep completely after just eight... Continue Reading

NYeC Digital Health: two diverging visions of a connected future (Part 1)

...tests are increasingly DIY, with smartphones capable of doing assays and Theranos’ inexpensive tests from a few drops of blood using microfluidics technology, available direct to consumer at a drugstore. Imaging devices are again smartphone based–CellScope‘s otoscope, Peek (eye) and GE’s VScan ultrasound (yes, it is still around) lead to less expensive home or retail-based physical exams. And the results would be owned by the patient. The PHR doesn’t go far enough for him–the patient would own their data, all of it, from day one. Medications are also expensive (in the US, the top ten drugs account for $62 bn... Continue Reading